Biohaven Pharmaceutical (NYSE:BHVN) Releases Earnings Results, Beats Expectations By $0.09 EPS

Biohaven Pharmaceutical (NYSE:BHVN) issued its quarterly earnings data on Tuesday, May 7th. The company reported ($1.41) EPS for the quarter, beating the consensus estimate of ($1.50) by $0.09, MarketWatch Earnings reports. During the same quarter in the previous year, the firm posted ($2.32) EPS.

BHVN traded down $2.20 during midday trading on Thursday, hitting $56.55. 524,456 shares of the company traded hands, compared to its average volume of 501,018. The stock has a market capitalization of $2.61 billion, a P/E ratio of -9.20 and a beta of 0.60. Biohaven Pharmaceutical has a 52 week low of $29.17 and a 52 week high of $65.64.

In other Biohaven Pharmaceutical news, insider John Tilton sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $50.11, for a total transaction of $501,100.00. Following the sale, the insider now owns 10,000 shares in the company, valued at approximately $501,100. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Declan Doogan sold 88,825 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $58.42, for a total transaction of $5,189,156.50. Following the sale, the director now owns 373,913 shares in the company, valued at approximately $21,843,997.46. The disclosure for this sale can be found here. Insiders have sold a total of 356,733 shares of company stock worth $18,672,281 in the last 90 days. Company insiders own 23.90% of the company’s stock.

BHVN has been the topic of a number of research analyst reports. Cantor Fitzgerald boosted their price objective on shares of Biohaven Pharmaceutical to $82.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Zacks Investment Research downgraded shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Oppenheimer reaffirmed a “buy” rating on shares of Biohaven Pharmaceutical in a research report on Tuesday, March 19th. Svb Leerink upped their target price on shares of Biohaven Pharmaceutical from $50.00 to $67.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 23rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 target price (up from $48.00) on shares of Biohaven Pharmaceutical in a research report on Monday, March 4th. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $69.91.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Rockland Register and is owned by of Rockland Register. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://rocklandregister.com/2019/05/30/biohaven-pharmaceutical-bhvn-releases-earnings-results-beats-expectations-by-0-09-eps.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Read More: Book Value Per Share – BVPS

Earnings History for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.